Flush with cash as a result of its mega-million dollar deal with Alexion on the development of drugs for rare diseases and a previous accord with AstraZeneca (The Pharma Letter January 15), privately-held US start up Moderna Therapeutics has announced the creation of Onkaido Therapeutics, a new venture focused exclusively on developing mRNA-based oncology treatments.
Onkaido Therapeutics will launch with $20 million in committed capital from Moderna. The new company will focus initially on 15 preclinical drug candidates in the areas of apoptosis, central regulatory nodes and immunotherapy. Several of these candidates are already under evaluation in in vivo disease models. By establishing Onkaido as a standalone unit, Moderna intends to accelerate the development of mRNA Therapeutics for oncology and deliver the potential of these new cancer treatments to patients.
Management line up
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze